Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

Nature Communications

Volumn 6, Issue , 2015, Pages

  Sausen, Mark ^a,b   Phallen, Jillian ^a   Adleff, Vilmos ^a   Jones, Siân ^b   Leary, Rebecca J ^a,k   Barrett, Michael T ^c,d   Anagnostou, Valsamo ^a   Parpart Li, Sonya ^b   Murphy, Derek ^b   Li, Qing Kay ^a   Hruban, Carolyn A ^a   Scharpf, Rob ^a   White, James R ^a   O'Dwyer, Peter J ^e   Allen, Peter J ^f   Eshleman, James R ^a,g   Thompson, Craig B ^f   Klimstra, David S ^f   Linehan, David C ^h   Maitra, Anirban ^a   Hruban, Ralph H ^a,g   Diaz, Luis A ^a   Von Hoff, Daniel D ^c,i   Johansen, Julia S ^j   Drebin, Jeffrey A ^e   Velculescu, Victor E ^a   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Personal Genome Diagnostics   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

ⁱ Virginia G Piper Cancer Center   (United States)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

^k NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG; TUMOR MARKER;

CANCER; DISEASE INCIDENCE; DNA; GENETIC ANALYSIS; GENOMICS; MORTALITY; MUTATION; TUMOR;

ARID1A GENE; ARTICLE; CANCER GENETICS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CDKN2A GENE; CLINICAL ARTICLE; CLINICAL OUTCOME; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DNA DETERMINATION; EXOME; FRAMESHIFT MUTATION; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN GENOME; HUMAN TISSUE; MLL GENE; MLL2 GENE; MLL3 GENE; NONSENSE MUTATION; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS BIOPSY; PANCREAS CANCER; PANCREAS RESECTION; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; SMAD4 GENE; SOMATIC MUTATION; TGFBR2 GENE; TP53 GENE; BLOOD; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; PANCREAS TUMOR; PHYSIOLOGY; PREDICTIVE VALUE; RECURRENT DISEASE; TREATMENT OUTCOME;

BIOMARKERS, TUMOR; DNA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; RECURRENCE; TREATMENT OUTCOME;

EID: 84987784586     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8686     Document Type: Article

References (29)

1. Siegel, Jr. R. L.Jr., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5-29 (2015).
2. Modolell, I., Guarner, L. & Malagelada, J. R. Vagaries of clinical presentation of pancreatic and biliary tract cancer. Ann. Oncol. 10(Suppl 4): 82-84 (1999).
3. Grover, S. & Syngal, S. Hereditary pancreatic cancer. Gastroenterology 139, 1076-1080 1080 e1-2 (2010).
4. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010).
5. Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399-405 (2012).
6. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
7. Paulson, A. S., Tran Cao, H. S., Tempero, M. A. & Lowy, A. M. Therapeutic advances in pancreatic cancer. Gastroenterology 144, 1316-1326 (2013).
8. Jones, S. et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci. Transl. Med. 7, 283ra53 (2015).
9. Jones, S. et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum. Mutat. 33, 100-103 (2012).
10. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
11. Goyama, S. & Mulloy, J. C. NF-kappaB: a coordinator for epigenetic regulation by MLL. Cancer Cell 24, 401-402 (2013).
12. Popovic, R. & Licht, J. D. Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov. 2, 405-413 (2012).
13. Jiao, Y. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199-1203 (2011).
14. Sausen, M. et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat. Genet. 45, 12-17 (2013).
15. Bettegowda, C. et al. Detection of circulating tumor DNA in early-And late-stage human malignancies. Sci. Transl. Med. 6, 224ra24 (2014).
16. Newman, A. M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20, 548-554 (2014).
17. Iacobuzio-Donahue, C. A., Velculescu, V. E., Wolfgang, C. L. & Hruban, R. H. Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin. Cancer Res. 18, 4257-4265 (2012).
18. Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950 (2011).
19. Fogelman, D. R. et al. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-Associated pancreatic cancer. Anticancer Res. 31, 1417-1420 (2011).
20. Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
21. van der Heijden, M. S. et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin. Cancer Res. 11, 7508-7515 (2005).
22. Villarroel, M. C. et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol. Cancer Ther. 10, 3-8 (2011).
23. Sorscher, S. M. Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancer. Cancer Invest. 29, 456-459 (2011).
24. Ramanathan, R. K. et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest. 22, 858-865 (2004).
25. Needleman, S. B. & Wunsch, C. D. A general method applicable to the search for similarities in the amino acid sequence of two proteins. J. Mol. Biol. 48, 443-453 (1970).
26. Cooper, G. M. et al. Distribution and intensity of constraint in mammalian genomic sequence. Genome Res. 15, 901-913 (2005).
27. Baggerly, K. A., Deng, L., Morris, J. S. & Aldaz, C. M. Differential expression in SAGE: accounting for normal between-library variation. Bioinformatics 19, 1477-1483 (2003).
28. Goeman, J. J. & Buhlmann, P. Analyzing gene expression data in terms of gene sets: methodological issues. Bioinformatics 23, 980-987 (2007).
29. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).